US 11,667,668 B2
Compositions and methods for treating CNS disorders
Francesco G. Salituro, Marlborough, MA (US); and Albert Jean Robichaud, Boston, MA (US)
Assigned to Sage Therapeutics, Inc., Cambridge, MA (US)
Filed by Sage Therapeutics, Inc., Cambridge, MA (US)
Filed on Dec. 8, 2021, as Appl. No. 17/545,290.
Application 17/545,290 is a continuation of application No. 16/770,398, abandoned, previously published as PCT/US2018/064546, filed on Dec. 7, 2018.
Claims priority of provisional application 62/731,539, filed on Sep. 14, 2018.
Claims priority of provisional application 62/596,725, filed on Dec. 8, 2017.
Prior Publication US 2022/0098231 A1, Mar. 31, 2022
Int. Cl. A61P 25/24 (2006.01); C07J 43/00 (2006.01)
CPC C07J 43/003 (2013.01) [A61P 25/24 (2018.01); C07B 2200/05 (2013.01)] 8 Claims
 
1. A compound of Formula (I-C)

OG Complex Work Unit Chemistry
selected from the group consisting of the compounds identified in the table below:
 
Compound
 
 
 
 
 
 
 
 
 
Number R3a R5 R6a R6b R17 R21a R21b Rm Rn
 
1 —CD3 H H H H H H H H
2 —CH3 D D H H H H H H
3 —CH3 H H H D H H H H
4 —CH3 H H H H D D H H
5 —CH3 H H H H H H D D
6 —CD3 H H H H D D D D
7 —CH3 H H H H D D D D
8 —CD3 H H H H H H D D
 
wherein any atom not labeled as deuterium is present at its natural isotopic abundance.